Randomized Study of Obicetrapib as an Adjunct to Statin Therapy
Part of paid clinical trials in Anniston, Alabama.
- Sponsor
- NewAmsterdam Pharma
- Study ID
- NCT04753606
- Phase
- PHASE2
- Status
- Completed
Conditions
- Dyslipidemias
- High Cholesterol
- Hypercholesterolemia
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- Obicetrapib — DRUGtablets
Study Details
This study will be a placebo-controlled, double-blind, randomized, phase 2 dose-finding study to evaluate the efficacy, safety, and tolerability of obicetrapib as an adjunct to high-intensity statin therapy.
Key Dates
- Start date
- Feb 18, 2021
- Status verified
- Sep 2021
- Primary completion
- May 24, 2021
- Completion
- Aug 30, 2021
Study Design
- Enrollment
- 120 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Placebo Comparator: Placeboonce-daily placebo
- Experimental: obicetrapib 5 mgonce-daily obicetrapib
- Experimental: obicetrapib 10 mgonce-daily obicetrapib
Primary Outcome Measure
Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [Friedewald] [ Time Frame: 8-weeks ]
Locations (19)
Find similar trials in Anniston, AL
By research site
Related Studies
- Alirocumab in Patients on a Stable Dialysis RegimenPHASE3 · Recruiting · Baylor Research Institute · Dallas, Texas
- Addressing Barriers to Achieving Cardiometabolic Disorders Prevention and Treatment Goals for PLWH in the SE USRecruiting · Duke University · Charlotte, North Carolina
- Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)PHASE2 · Recruiting · Priscilla Hsue, MD · Los Angeles, California
- Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders TrialPHASE2 · Recruiting · Wake Forest University Health Sciences · Winston-Salem, North Carolina